Exact Mass: 555.1813
Exact Mass Matches: 555.1813
Found 215 metabolites which its exact mass value is equals to given mass value 555.1813
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Demethyldecarbamoylnovobiocin
A hydroxycoumarin that is novobiocin lacking the 3-O-carbamoyl and 4-O-methyl groups from the hexose ring.
Tiapamil
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
15-Demethylaclacinomycin T
An anthracycline obtained by hydrolysis of the methyl ester group of aclacinomycin T.
Fiduxosin
Rociletinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
N-Fructosyl S-(2-carboxypropyl)glutathione
Annotation level-3
Isoflavone base + 1O, 1MeO, O-Hex+C7H12NO
Annotation level-3
1Z,-Isomer-Tunichrome An1|tunichrome B-1|Tunichrome B1
alpha-L-Delta4,5HexpA-(1->3)-beta-D-GalpNAc-(1->4)-D-GlcpA
2-amino-5-[(5-beta-D-glucopyranosyl-4-hydroxy-cyclopent-2-enylamino)-methyl]-7-beta-D-ribofuranosyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one
2-Desoxy-[5]adenylsaeure-thymidin-3-ylester|d(TpA)|TA|thymidilyl-(3<*>5)-2-deoxyadenosine|thymidylyl-(3->5)-2-deoxy-adenosine|TpA|TpdA
Cys Asp Arg Tyr
Cys Asp Tyr Arg
Cys Phe Met Arg
Cys Phe Arg Met
Cys Phe Thr Trp
Cys Phe Trp Thr
Cys Met Phe Arg
Cys Met Arg Phe
Cys Arg Asp Tyr
Cys Arg Phe Met
Cys Arg Met Phe
Cys Arg Tyr Asp
Cys Thr Phe Trp
Cys Thr Trp Phe
Cys Trp Phe Thr
Cys Trp Thr Phe
Cys Tyr Asp Arg
Cys Tyr Arg Asp
Asp Cys Arg Tyr
Asp Cys Tyr Arg
Asp Met Gln Tyr
Asp Met Tyr Gln
Asp Gln Met Tyr
Asp Gln Tyr Met
Asp Arg Cys Tyr
Asp Arg Tyr Cys
Asp Tyr Cys Arg
Asp Tyr Met Gln
Asp Tyr Gln Met
Asp Tyr Arg Cys
Glu Met Asn Tyr
Glu Met Tyr Asn
Glu Asn Met Tyr
Glu Asn Tyr Met
Glu Tyr Met Asn
Glu Tyr Asn Met
Phe Cys Met Arg
Phe Cys Arg Met
Phe Cys Thr Trp
Phe Cys Trp Thr
Phe Met Cys Arg
Phe Met Met Gln
Phe Met Gln Met
Phe Met Arg Cys
Phe Gln Met Met
Phe Arg Cys Met
Phe Arg Met Cys
Phe Thr Cys Trp
Phe Thr Trp Cys
Phe Trp Cys Thr
Phe Trp Thr Cys
Gly Met Trp Tyr
Gly Met Tyr Trp
Gly Trp Met Tyr
Gly Trp Tyr Met
Gly Tyr Met Trp
Gly Tyr Trp Met
Met Cys Phe Arg
Met Cys Arg Phe
Met Asp Gln Tyr
Met Asp Tyr Gln
Met Glu Asn Tyr
Met Glu Tyr Asn
Met Phe Cys Arg
Met Phe Met Gln
Met Phe Gln Met
Met Phe Arg Cys
Met Gly Trp Tyr
Met Gly Tyr Trp
Met Met Phe Gln
Met Met Gln Phe
Met Asn Glu Tyr
Met Asn Tyr Glu
Met Gln Asp Tyr
Met Gln Phe Met
Met Gln Met Phe
Met Gln Tyr Asp
Met Arg Cys Phe
Met Arg Phe Cys
Met Trp Gly Tyr
Met Trp Tyr Gly
Met Tyr Asp Gln
Met Tyr Glu Asn
Met Tyr Gly Trp
Met Tyr Asn Glu
Met Tyr Gln Asp
Met Tyr Trp Gly
Asn Glu Met Tyr
Asn Glu Tyr Met
Asn Met Glu Tyr
Asn Met Tyr Glu
Asn Tyr Glu Met
Asn Tyr Met Glu
Gln Asp Met Tyr
Gln Asp Tyr Met
Gln Phe Met Met
Gln Met Asp Tyr
Gln Met Phe Met
Gln Met Met Phe
Gln Met Tyr Asp
Gln Tyr Asp Met
Gln Tyr Met Asp
Arg Cys Asp Tyr
Arg Cys Phe Met
Arg Cys Met Phe
Arg Cys Tyr Asp
Arg Asp Cys Tyr
Arg Asp Tyr Cys
Arg Phe Cys Met
Arg Phe Met Cys
Arg Met Cys Phe
Arg Met Phe Cys
Arg Tyr Cys Asp
Arg Tyr Asp Cys
Thr Cys Phe Trp
Thr Cys Trp Phe
Thr Phe Cys Trp
Thr Phe Trp Cys
Thr Trp Cys Phe
Thr Trp Phe Cys
Trp Cys Phe Thr
Trp Cys Thr Phe
Trp Phe Cys Thr
Trp Phe Thr Cys
Trp Gly Met Tyr
Trp Gly Tyr Met
Trp Met Gly Tyr
Trp Met Tyr Gly
Trp Thr Cys Phe
Trp Thr Phe Cys
Trp Tyr Gly Met
Trp Tyr Met Gly
Tyr Cys Asp Arg
Tyr Cys Arg Asp
Tyr Asp Cys Arg
Tyr Asp Met Gln
Tyr Asp Gln Met
Tyr Asp Arg Cys
Tyr Glu Met Asn
Tyr Glu Asn Met
Tyr Gly Met Trp
Tyr Gly Trp Met
Tyr Met Asp Gln
Tyr Met Glu Asn
Tyr Met Gly Trp
Tyr Met Asn Glu
Tyr Met Gln Asp
Tyr Met Trp Gly
Tyr Asn Glu Met
Tyr Asn Met Glu
Tyr Gln Asp Met
Tyr Gln Met Asp
Tyr Arg Cys Asp
Tyr Arg Asp Cys
Tyr Trp Gly Met
Tyr Trp Met Gly
alkali blue 4b
Serlopitant
D018377 - Neurotransmitter Agents > D064729 - Neurokinin-1 Receptor Antagonists C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent
Rucaparib Camsylate
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C62554 - Poly (ADP-Ribose) Polymerase Inhibitor C471 - Enzyme Inhibitor
N-(Ethylsulfonyl)tryptophyl-N~1~-{4-[amino(imino)methyl]benzyl}glutamamide
Rociletinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
(7,7-Dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl)methanesulfonic acid;6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
(1R,2R,4S)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-3-(dimethylazaniumyl)-alpha-L-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
(2R)-3-hydroxy-2-{[6-O-(6-O-octanoyl-alpha-D-glucopyranosyl)-alpha-D-glucopyranosyl]oxy}propanoate
(2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-3-[[(1S,2R,4R,7Z,11S)-4,8-dimethyl-13-oxo-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-12-yl]methylsulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
2-O-[6-O-Octanoyl-alpha-D-glucopyranosyl-(1->6)-alpha-D-glucopyranosyl]-D-glycerate
3-(4-fluorophenyl)-1-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
3-(4-fluorophenyl)-1-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-8-(2-methylphenyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea
(3R)-2-[(R)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(pyridin-4-ylmethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-[(E)-prop-1-enyl]-4,5-dihydro-3H-6,1lambda6,2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-[4-(trifluoromethyl)phenyl]urea
(3S)-2-[(S)-tert-butylsulfinyl]-3-(2-hydroxyethyl)-N-(pyridin-4-ylmethyl)-4-(3-pyridin-4-ylphenyl)-1,3-dihydropyrrolo[3,4-c]pyridine-6-carboxamide
15-demethylaclacinomycin T zwitterion
A zwitterion obtained by transfer of a proton from the carboxy to the tertiary amino group of 15-demethylaclacinomycin T.
Tiapamil
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
3-vinylbacteriochlorophyllide d(1-)
A cyclic tetrapyrrole anion that is the conjugate base of 3-vinylbacteriochlorophyllide d, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(rel)-AR234960
(rel)-AR234960 is an active relative configuration of AR234960. AR234960, a non-peptide MAS (a G protein-coupled receptor) agonist, increases both mRNA and protein levels of CTGF via ERK1/2 signaling in HEK293-MAS cells and adult human cardiac fibroblasts[1].